الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
The present study is conducted to investigate the possible anti-fibrotic effect of unique drugs that target more than one site in the pathogenesis of liver fibrosis, and to compare their possible effects with other model drugs which have sole receptor targeting. On the other hand, we aimed to evaluate the effect of UDCA, a drug with multiple mechanisms of actions, by two different doses on non cholestatic liver fibrosis. The study also searched for probable mechanisms for the emerging results.
In the present experiment, adult male albino rats (200-300 g) were divided into 3 sets, each set consisting of 6 groups. First set studied the effect of telmisartan (PPARγ agonist and ARB) versus losartan (ARB) on TAA-induced HF. While second set explored the effect of bezafibrate (PPARα and PPARγ agonist) versus pioglitazone (PPARγ agonist) on TAA model of HF. Finally, the third set focusing on UDCA effect by two diferent doses on experimental HF. In addition we targeted HCSc, inducible nitric oxide (iNOS), caspase-3 and TIMP-1 expression in hepatic tissue to clarify the mechanisms for the potential effects of tested drugs.
The experimental model of HF was established by TAA (50 mg/kg) injected i.p. into rats twice weekly for 6 weeks and treatments started concurrently with TAA injection. In the first set, rats were divided into the following groups; group 1: Normal control group (non-treated), group 2: Telmisartan control rats, group 3: Losartan control rats, group 4: HF control group (TAA-treated), group 5: TAA+telmisartan-treated rats, group 6: TAA+losartan-treated group. Second set rats distributed as follow; group 1: Normal control rats, group 2: Bezafibrate control rats, group 3: Pioglitazone control rats, group 4: HF control rats, group 5: TAA+bezafibrate-treated rats, group 6: TAA+pioglitazone-treated rats. While in the third set, animals were allocated into the following groups; group 1: Normal control rats, group 2: UDCA (25 mg/kg) control rats, group 3: UDCA (50 mg/kg) control rats, group 4: HF control rats, group 5: TAA+UDCA (25 mg/kg)-treated rats, group 6: TAA+UDCA (50 mg/kg)-treated group.